The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.

ABSTRACT:

Background

Although antimicrobial susceptibility testing (AST) frequently guides cystic fibrosis (CF) pulmonary exacerbation (PEx) management, its clinical utility is unclear. This study examined associations between AST and antimicrobial switching during PEx treatment and time and occurrence of next PEx as treatment outcomes.

Methods

This retrospective cohort study utilized Pediatric Health Information System data. Children and adolescents aged 1-18 years admitted for a PEx from 2011 to 2016 were studied. Antimicrobial switching was defined as any intra-admission change in intravenous (IV), oral, and/or inhaled antimicrobials. Time to next PEx was defined as the time between index PEx hospital discharge and subsequent hospital admission requiring IV antimicrobials. Odds of

SUBMITTER: Cogen JD 

PROVIDER: S-EPMC6881516 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature